Wise Up Journal
By Gabriel O’Hara
Below are two articles from the Daily Mail and the Times giving coverage to this new michochipped medicine. These are followed by extracts from the producer’s publications showing that they have powerful backing, supported by the World Economic Forum and partly funded by the infamous Carlyle Group.
By Jo Macfarlane
Microchip that tells the GP if you’ve taken your pills
Microchips in pills could soon allow doctors to find out whether a patient has taken their medication.
The digestible sensors, just 1mm wide, would mean GPs and surgeons could monitor patients outside the hospital or surgery.
Developers say the technology could be particularly useful for psychiatric or elderly patients who rely on a complicated regime of drugs – and are at risk if they miss a dose or take it at the wrong time.
It could also be used for the chronically ill, such as people with heart disease, to establish whether costly drugs are working or whether they are causing potentially dangerous side effects.
The sensors could even remind women to take the Pill if they forget.
The ‘intelligent’ medicine works by activating a harmless electric charge when drugs are digested by the stomach.
This charge is picked up by a sensing patch on the patients’ stomach or back, which records the time and date that the pill is digested. It also measures heart rate, motion and breathing patterns.
The information is transmitted to a patient’s mobile phone and then to the internet using wireless technology, to give a complete picture of their health and the impact of their drugs.
Doctors and carers can view this information on secure web pages or have the information sent to their mobile phones.
The silicon microchips are invisible to patients and can be added to any standard drug during the manufacturing process.
Two major drugs companies are investigating the technology, developed by US-based Proteus Biomedical. Trials are to begin in the UK within 12 months.
Professor Nick Peters, a cardiologist at Imperial College London, who is co-ordinating
trials, said the technology was ‘transformative’.
‘This is all about empowering patients and their families because it measures wellness, and people can actually be tracked getting better,’ he said.
‘Psychologically speaking, that’s hugely helpful for patients and enormously reassuring for carers.
‘Normally patients would have to be in hospital to get this level of feedback, so the hope is that it frees up beds and saves the NHS money.’
a Silicon Valley company called Proteus Biomedical is developing what it calls the Raisin system of microchipped pills to help to tackle the problems of patients forgetting or refusing to take medicines. Each pill contains a microchip that can send data to a receiver in a patch or under the skin. The company hopes to have the system on the market in 2011.
Proteus Biomedical Raises $32 Million in Series D Funding
New corporate investors Medtronic and Itochu join existing investors St. Jude Medical,
Adams Street Partners, The Carlyle Group, Essex Woodlands, Kaiser Permanente Ventures,
Spring Ridge Ventures and others.
Proteus Biomedical Honored by World Economic Forum
Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the company has been selected a 2009 Technology Pioneer by the World
The Technology Pioneer Award honors 34 visionary companies from around the world that a
panel of 44 global technology experts believes will have a deep impact on business and society. To be selected, a company must be involved in the development of life-changing technology innovation, demonstrate visionary leadership, and show signs of being a long-standing market leader.
We congratulate Proteus Biomedical for their remarkable achievements and welcome them to
the wider community of the World Economic Forum. During these difficult times, we are certain that the technologies driven by these visionary companies will contribute to the next wave of growth, with the innovative and entrepreneurial spirit that characterizes them,” said André Schneider, Managing Director and Chief Operating Officer of the World Economic Forum.
As a 2009 Technology Pioneer, Proteus Biomedical has been invited to participate in the World Economic Forum’s Annual Meeting in Davos-Klosters, Switzerland, Jan. 28 through Feb. 1, 2009 and the Annual Meeting of the New Champions in Dalian, China, Sept. 10 – 12. These two events bring together the world’s foremost thought leaders in business and government.
The company’s implantable ChipSkin™ technology adds intelligence to any implanted medical device: tiny active electronics that expand the performance of devices that use electrical energy to deliver therapy inside the body.
Proteus ingestible event markers (IEMs) are tiny, digestible sensors made from food ingredients, which are activated by stomach fluids after swallowing. Once activated, the IEM sends an ultra low-power, private, digital signal through the body to a microelectronic receiver that is either a small bandage style skin patch or a tiny device insert under the skin. The receiver date- and time-stamps, decodes, and records information such as the type of drug, the dose, and the place of manufacture, as well as measures and reports physiologic measures such as heart rate, activity, and respiratory rate.
The IEM is manufactured on silicon wafers, and is extremely economical to produce, costing a few cents per sensor in large quantities.
The IEM is the cornerstone of the company’s Raisin™ System, which is currently in clinical development. The Raisin™ System measures the body’s response to medications and is intended to improve the management of chronic diseases like heart failure, infectious disease and psychiatric disorders.
One of the significant challenges preventing widespread use of implanted medical device therapies is the disintegration of active electronics upon exposure to body fluids. Proteus’ ChipSkin™ technology eliminates this issue by providing an extremely thin and durable protective layer that ensures long-term survival and performance of micro-scale implanted devices. ChipSkin enables any implanted medical device to contain active electronics and dramatically expands the capability of existing implanted devices that utilize electrical energy to stimulate, pace or regulate body function. For example, providing 32 locations to pace the left side of the heart instead of only two or four, improving the clinical efficacy of cardiac resynchronization therapy.
Mp3: Alan Watt *